Cardiovascular Prevention Clinical Trial
Official title:
Red Blood Cell 2,3-biphosphoglycerate Levels in Patients Treated With Empagliflozin. A Prospective Cohort Study.
The aim of this study is to investigate the hypothesis that treatment with empagliflozin may have an impact on red blood cell 2,3-biphosphoglycerate levels affecting tissue oxygen supply and thus mediating part of the cardio- and reno- protective effect of SGLT-2 inhibitors.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01888575 -
Assessment of Low-dose ASA Discontinuation Risk Associated With Concomitant PPI Use During the First Year of ASA Therapy
|
N/A | |
| Recruiting |
NCT05884840 -
New Cardiovascular Risk Screening Strategy.
|
N/A | |
| Enrolling by invitation |
NCT04450914 -
Implementing Shared Decision Making (SDM) For Individualized CV Prevention (SDM4IP)
|
N/A | |
| Completed |
NCT03488797 -
Web-based Motor Intervention to Increase Health Related Physical Fitness in Children With Congenital Heart Disease
|
N/A | |
| Recruiting |
NCT05659498 -
Cardiac Rehabilitation for Cardiovascular Risk Reduction in People With Severe and Persistent Mental Illness
|
N/A | |
| Recruiting |
NCT05226806 -
Connect2Move: Valorization of Natural Cardio Trekking Hiking Trails
|
||
| Not yet recruiting |
NCT06362538 -
The Cardiovascular Prevention Program
|
N/A |